未登录 分享 收藏
分享 收藏
Trilaciclib prior to FOLFOXIRI/bevacizumab for patients with untreated metastatic colorectal cancer: phase 3 PRESERVE 1 trial Lenz, Heinz-Josef; Liu, Tianshu; Chen, Emerson Y.; Horvath, Zsolt; Bondarenko, Igor; Danielewicz, Iwona; Ghidini, Michele; Garcia-Alfonso, Pilar; Jones, Robert; Aapro, Matti; Zhang, Yanqiao; Wang, Jufeng; Wang, Wayne; Adeleye, Jennifer; Beelen, Andrew; Hubbard, Joleen 分享 收藏
Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment CDK4/CDK6抑制剂在激素受体阳性乳腺癌治疗中的敏感性和耐药机制 Glaviano, Antonino; Wander, Seth A.; Baird, Richard D.; Yap, Kenneth C. -H.; Lam, Hiu Yan; Toi, Masakazu; Carbone, Daniela; Geoerger, Birgit; Serra, Violeta; Jones, Robert H.; Ngeow, Joanne; Toska, Eneda; Stebbing, Justin; Crasta, Karen; Finn, Richard S.; Diana, Patrizia; Vuina, Karla; de Bruin, Robertus A. M.; Surana, Uttam; Bardia, Aditya; Kumar, Alan Prem 分享 收藏
Safety and tolerability of long-term treatment with darolutamide in patients with metastatic castration-resistant prostate cancer Jones, Robert Hugh; Fizazi, Karim; James, Nicholas D.; Tammela, Teuvo L.; Matsubara, Nobuaki; Priou, Frank; Beuzeboc, Philippe; Lesimple, Thierry; Bono, Petri; Kataja, Vesa; Garcia, Jorge A.; Protheroe, Andrew; Shore, Neal; Aspegren, John; Joensuu, Heikki; Kuss, Iris; Fiala-Buskies, Sabine; Vjaters, Egils 分享 收藏
Efficacy and safety outcomes of darolutamide in patients with non-metastatic castration-resistant prostate cancer with comorbidities and concomitant medications from the randomised phase 3 ARAMIS trial 来自ARAMIS随机3期试验的达鲁柳胺对伴合并症和合并用药的非转移性去势抵抗性前列腺癌患者的疗效和安全性 Fizazi, Karim; Shore, Neal D.; Smith, Matthew; Ramos, Rodrigo; Jones, Robert; Niegisch, Guenter; Vjaters, Egils; Wang, Yuan; Srinivasan, Shankar; Sarapohja, Toni; Verholen, Frank 分享 收藏
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer PI3K/AKT/mTOR信号转导通路与肿瘤靶向治疗 Glaviano, Antonino; Foo, Aaron S. C.; Lam, Hiu Y.; Yap, Kenneth C. H.; Jacot, William; Jones, Robert H.; Eng, Huiyan; Nair, Madhumathy G.; Makvandi, Pooyan; Geoerger, Birgit; Kulke, Matthew H.; Baird, Richard D.; Prabhu, Jyothi S.; Carbone, Daniela; Pecoraro, Camilla; Teh, Daniel B. L.; Sethi, Gautam; Cavalieri, Vincenzo; Lin, Kevin H.; Javidi-Sharifi, Nathalie R.; Toska, Eneda; Davids, Matthew S.; Brown, Jennifer R.; Diana, Patrizia; Stebbing, Justin; Fruman, David A.; Kumar, Alan P. 分享 收藏
A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer Macaulay, Valentine M.; Lord, Simon; Hussain, Syed; Maroto, Jose Pablo; Jones, Robert Hugh; Climent, Miguel Angel; Cook, Natalie; Lin, Chia-Chi; Wang, Shian-Shiang; Bianchini, Diletta; Bailey, Mark; Schlieker, Laura; Bogenrieder, Thomas; de Bono, Johann 分享 收藏
分享 收藏
A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer Kristeleit, Rebecca; Plummer, Ruth; Jones, Robert; Carter, Louise; Blagden, Sarah; Sarker, Debashis; Arkenau, Tobias; Evans, Thomas R. Jeffry; Danson, Sarah; Symeonides, Stefan N.; Veal, Gareth J.; Klencke, Barbara J.; Kowalski, Mark M.; Banerji, Udai 分享 收藏
分享 收藏
分享 收藏
Breast cancer survivors exhibit an accumulation of CD4+central memory T cells, a fall in CD8+naive T cells and higher activation of CD4+/CD8+memory T cells in blood, which is positively correlated with age and fat mass index Echarri, Ainhoa Arana; Struszczak, Lauren; Beresford, Mark; Campbell, John P.; Jones, Robert H.; Butler, Rachel; Thompson, Dylan; Turner, James E. 分享 收藏
H3B-6545, a novel selective estrogen receptor covalent antagonist (SERCA), in estrogen receptor positive (ER plus ), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer - A phase II study Hamilton, Erika P.; Wang, Judy S.; Pluard, Timothy; Morikawa, Aki; Dees, E. Claire; Jones, Robert H.; Haley, Barbara; Armstrong, Anne; Cohen, Adam L.; Munster, Pamela; Wright, Gail S.; Kayali, Fadi; Cantagallo, Lisa; Korpal, Manav; Long, Jenny; Xiao, Jianjun; Destenaves, Benoit; Gao, Lei; Sahmoud, Tarek; Gualberto, Antonio; Juric, Dejan 分享 收藏
Abiraterone acetate plus prednisolone (AAP) with or without enzalutamide (ENZ) added to androgen deprivation therapy (ADT) compared to ADT alone for men with high-risk non-metastatic (M0) prostate cancer (PCa): Combined analysis from two comparisons in the STAMPEDE platform protocol Attard, G.; Brown, L. C.; Clarke, N.; Murphy, L.; Cross, W.; Jones, R.; Gillessen, S.; Russell, J. M.; Cook, A.; Bowen, J.; Lydon, A.; Pedley, I. D.; Parikh, O.; Chowdhury, S.; Malik, Z.; Matheson, D.; Parker, C.; Sydes, M. R.; Parmar, M. K.; James, N. D. 分享 收藏
分享 收藏
Vandetanib plus fulvestrant versus placebo plus fulvestrant after relapse or progression on an aromatase inhibitor in metastatic ER positive breast cancer (FURVA): A randomised, double-blind, placebo-controlled, phase II trial Jones, R.; Casbard, A.; Carucci, M.; Smith, J.; Ingarfield, K.; Gee, J. M. W.; Hudson, Z.; Alchami, F.; Hayward, L.; Hickish, T.; Hwang, D.; McAdam, K.; Spensley, S.; Waters, S.; Wheatley, D.; Beresford, M. 分享 收藏
ODM-204, a Novel Dual Inhibitor of CYP17A1 and Androgen Receptor: Early Results from Phase I Dose Escalation in Men with Castration-resistant Prostate Cancer Peltola, Katriina J.; Bono, Petri; Jones, Robert Hugh; Vjaters, Egils; Nykanen, Pirjo; Vuorela, Annamari; Oksala, Riikka; Pohjanjousi, Pasi; Mustonen, Mika V. J.; Fizazi, Karim; Massard, Christophe 分享 收藏
Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer Basu, B.; Krebs, M. G.; Sundar, R.; Wilson, R. H.; Spicer, J.; Jones, R.; Brada, M.; Talbot, D. C.; Steele, N.; Garces, A. H. Ingles; Brugger, W.; Harrington, E. A.; Evans, J.; Hall, E.; Tovey, H.; de Oliveira, F. M.; Carreira, S.; Swales, K.; Ruddle, R.; Raynaud, F. I.; Purchase, B.; Dawes, J. C.; Parmar, M.; Turner, A. J.; Tunariu, N.; Banerjee, S.; de Bono, J. S.; Banerji, U. 分享 收藏
Safety, pharmacokinetics (PK) & pharmacodynamics (PD) of idasanutlin (idasa), combined with abiraterone (abi)/prednisolone (pred) or enzalutamide (enza) in castrate resistant prostate cancer (CRPC) Roxburgh, Patricia; Currie, Dawn; Morrison, Paula; Kelly, Caroline; Thomson, Fiona; McCormick, Carol; Bilsland, Alan; Jones, Robert H.; Quinton, Amy; McCartney, Elaine; Barwell, Lorraine; Jones, Rob J. 分享 收藏
.png){kind=icon}
.png){kind=icon}
.png)
ANNALS OF ONCOLOGY.png)
OAAI
.png){kind=icon}
分享.png){kind=icon}
收藏